Video Assisted Pericardioscopic Surgery: Minimal-invasive Implantation of Epimyocardial Pacemaker Leads in Humans (VAPS)
Dysrhythmia, Cardiac, Heart Failure, Pacemaker Electrode Infection
About this trial
This is an interventional treatment trial for Dysrhythmia, Cardiac
Eligibility Criteria
Inclusion Criteria:
This study will include patients who are planned to undergo a pacemaker therapy within their regular medical care and who are eligible for an alternative approach for lead placement (minimal-invasive pericardioscopic surgery):
I. Patients fulfilling current, sophisticated criteria for cardiac resynchronisation therapy (CRT) (e.g. patients with symptomatic heart failure independent of functional class, prolonged QRS-duration (especially left bundle branch block), severely depressed systolic left ventricular function), but have a history of failed CRT lead implantation or showed insufficient resynchronization after conventional CRT treatment, OR
II. Haemodialysis patients fulfilling the criteria for an implantation of a cardiac pacemakers due to bradycardiac dysrhythmia, OR
III. Patients suffering from acute pacemaker-lead-infection, who require system-explantation and concomitant implantation of a new system
Further inclusion criteria:
- Patients aged 18 years or above
- Adults who are contractually capable and mentally able to understand and follow the instructions of the study personnel.
- Signed informed consent prior to study participation.
Exclusion Criteria:
- Euro Score II (http://www.euroscore.org/calc.html) > 20 %
- Patients in NYHA functional class IV
- Previous cardiac surgery / sternotomy
- Previous pericarditis
- Gender-independent myocardial wall thickness less than 5 mm
- Coexisting cardiac/vessel aneurysmata
- Patients with myocardial infarction within the last 4 weeks
- Pregnancy and breast-feeding
- Patients who are accommodated at judicial or official requests
- Patients with known anomalies of the cardiac anatomy
- Patients for whom beclometasone dipropionate is contraindicated
- Patients with bleeding disorders and coagulopathy
- Patients with a life expectancy below 12 months
Sites / Locations
- University Hospital RWTH Aachen
Arms of the Study
Arm 1
Experimental
Treatment
StingrayTM, Medtronic®